Immunex Message Board - Msg: 14298978

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Yang who started this subject	8/30/2000 9:36:12 AM
From: manfredhasler	of 656

ANALYSTS’ CONSENSUS ESTIMATE: Hold (As of 8/27/00) Followed by 18 Wall Street professionals, Immunex stock is considered a "Hold." The weighted consensus ranking or AQO of the company is 0.71. This value lies inside the .35 and .749 AQO range considered necessary for a "Hold" recommendation. The current AQO of the S&P 500 is 0.82, indicating the shares' performance is likely to be less attractive than the general market as reflected in the S&P 500. Based on industry analysts' estimates, Immunex's earnings are expected to increase in both 2000 and 2001. At this time, an increase of 221.4% is expected over last year's earnings of $0.08 per share, and a further increase of 11.1% is anticipated next year. This implies earnings of $0.27 per share in 2000 and earnings of $0.30 per share in 2001. Economists expect the S&P 500 will show a rise in earnings in 2000 of about 10.11% and will show a gain of 5.42% in 2001. From the perspective of these projections and taking into account the growth foreseen for the S&P 500, earnings at Immunex are expected to grow at a higher rate than that anticipated for the broad market in both 2000 and 2001. The first quarter profit projection from analysts for Immunex indicates the financial markets are expecting the company to report earnings of $0.06 per share. While this current estimate reflects no change from the prior month, it still indicates that analysts believe earnings will rise over the $0.00 per share recorded in the prior year earlier quarter by 5900.00%. Confidence by Wall Street in the forecast of earnings for Immunex is at the top of the scale statistically. The deviation in the estimates that form the consensus is very low and any significant variation from expected results could have very adverse price consequences for the shares. siliconinvestor.multexinvestor.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next